Screening for hepatitis B, hepatitis C and HIV using a dried blood spot
Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot
This project will try a simple dried blood spot test to check people who use drugs for hepatitis B, hepatitis C and HIV.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Rouen Academic / other |
| Locations | 11 sites (Avranches and 10 other locations) |
| Trial ID | NCT05390424 on ClinicalTrials.gov |
What this trial studies
This project uses dried blood spot sampling to screen for hepatitis B, hepatitis C, and HIV among people with current or past injection or nasal drug use and people on opioid substitution therapy. Capillary blood is collected onto filter paper and sent for laboratory testing for viral markers, enabling testing outside standard phlebotomy settings. Individuals with known active viral infections are excluded so the focus is on finding undiagnosed infections. The approach aims to improve reach of screening within addiction services and community sites in Normandy.
Who should consider this trial
Good fit: Ideal candidates are current or former intravenous or nasal drug users, including people on opiate substitution therapy, who do not have a known active viral infection.
Not a fit: People who already have a confirmed active hepatitis B, hepatitis C, or HIV infection or those who are not drug users are unlikely to benefit from this screening approach.
Why it matters
Potential benefit: If successful, this could detect infections earlier in people who use drugs and help link them to care using a minimally invasive, easy-to-use test.
How similar studies have performed: Dried blood spot testing for HIV, hepatitis B and C has been validated in multiple studies and is increasingly used to expand screening, so the approach is supported by prior evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Former or active intravenous and/or nasal drug user * Person on opiate substitution therapy Exclusion Criteria: * Person with known active viral infection(s)
Where this trial is running
Avranches and 10 other locations
- Caarud Sud Manche — Avranches, France (Recruiting)
- Csapa Barentin — Barentin, France (Recruiting)
- Oeuvre Normande Des Meres — Dieppe, France (Recruiting)
- Csapa Act — Elbeuf, France (Recruiting)
- Csapa Gisors — Gisors, France (Recruiting)
- Csapa Nautilia — Le Havre, France (Recruiting)
- Csapa Pont-Audemer — Pont-Audemer, France (Recruiting)
- Aides Region Normandie — Rouen, France (Recruiting)
- Csapa-Caarud La Boussole — Rouen, France (Recruiting)
- Chu Rouen — Rouen, France (Recruiting)
- Csapa Caux Et Bray — Yvetot, France (Recruiting)
Study contacts
- Principal investigator: Ghassan RIACHI, MD — University Hospital, Rouen
- Study coordinator: Ghassan RIACHI, MD
- Email: ghassan.riachi@chu-rouen.fr
- Phone: +3323288
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.